Positive results show that C21 can become an important complement to COVID-19 vaccines

▴ Positive results show that C21 can become an important complement to COVID-19 vaccines
Vicore Pharma, data show restoration of lung function in COVID-19 with the company's oral lead candidate drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.

Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today reports an expanded data analysis to follow up the encouraging top-line data from the ATTRACT study reported on December 8, 2020. The data show restoration of lung function in COVID-19 with the company's oral lead candidate drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic. A webcast presentation will be held today at 15:00 CET (9:00 am EST).

With COVID-19 increasing worldwide, with more than 600,000 new cases and 10,000 deaths registered per day, there is an urgent need for a safe oral effective therapy as an important complement to the recently launched vaccine efforts.

"The critical incident in COVID-19 that makes this disease different from a common cold is the progression to the distal airways with respiratory distress and subsequent need for oxygen supplementation", said Carl-Johan Dalsgaard, CEO of Vicore Pharma. "Our data clearly show that C21 can restore lung function on top of steroids and normalize gas exchange. A safe oral medication with such properties can become an important complement to vaccines to combat the pandemic".

Updated summary of results   

C21 gradually lowered the risk for patients needing oxygen supplementation with reductions of 40% (p=0.057) at the end of the 7-day treatment and 57% (p=0.014) at day 8 after the start of treatment. At the end of the trial, about a week after the last dose of C21, the effect was even more pronounced, with only one patient in the C21 group still needing oxygen supplementation compared to 11 patients in the placebo group - a reduction by >90% (p<0.002). In the subgroup of patients needing oxygen supplementation (about 30 patients per treatment group), C21 produced a greater reduction of CRP (C-reactive protein) than in the placebo group, an effect that was statistically significant at the predefined 10% level. As reported on December 8, there was a clear trend for C21 reducing the number of patients needing mechanical ventilation and a trend for C21 reducing mortality. The data also showed that the treatment was safe and well-tolerated.

The reduced need for oxygen supplementation indicates that C21 stops virus-induced pathological processes in the distal airways and thereby restores lung function. The improvement developed gradually and became more pronounced after the treatment period, and the results suggest that C21 may also be capable of preventing respiratory damage caused by the virus, and in doing so the development of COVID-19. 

Study design     

In the ATTRACT study (Angiotensin II Type Two Receptor Agonist COVID-19 Trial), a randomized, double-blind and placebo-controlled trial, a total of 106 hospitalized patients with a diagnosis of coronavirus SARS-CoV-2 infection (confirmed by polymerase chain reaction test) and signs of acute respiratory infection but not requiring mechanical ventilation were recruited. The patients were randomized to receive oral treatment with C21 (100 mg b.i.d., n=51) or placebo (n=56) for seven days on top of standard of care (physician's choice) with a follow up after 7-10 days.  According to data analyzed to date, the treatment groups were well balanced regarding age, sex, and concomitant medications.  Importantly, the vast majority of patients received corticosteroid treatment.

C21, a first-in-class AT2R agonist                          
C21 is a first-in-class orally available low molecular weight angiotensin II type 2 receptor (AT2R) agonist that activates the "protective arm" of the renin-angiotensin system (RAS). The compound has shown robust effects in human IPF lung slices, and a phase II proof-of-concept study in IPF has recently started. Given that AT2R agonism has therapeutic potential in a number of additional indications with significant unmet needs, Vicore Pharma has intensified the efforts to develop proprietary follow-up molecules with different profiles.

Tags : #VicorePharma #ATTRACTStudy #RestorationofLungFunction #Covid-19 #C21 #Covid-19Vaccine #JohanDaisgaard #AT2RAgonist #FightAgainstCovid-19

About the Author


Rohit Sharma

Writer, Health Enthusiast, and an Accountant, Rohit Sharma is a writer at medicircle, penning down his thoughts about healthcare research, innovations, trends in healthcare and simply all about healthcare. Write to rohit on [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

PM addresses the Nation today, announces free vaccinesJune 07, 2021
Why inhalers are best for treating asthma, well illustrated by Dr. Anil SingalMay 12, 2021
Dr. Rohan Palshetkar shares his invaluable insights about the Maternal Mortality Rate causes and improvements in India April 29, 2021
It is important to adopt a non-judgmental attitude towards any teenage girl seeking contraceptive advise suggests Dr. Teena Trivedi, Obstetrician and GynecologistApril 16, 2021
80% of the diseases are psychosomatic which means they have roots in the mind and this is where homeopathy steps in - It resolves physical ailments by finding the cause in the mind – Dr. Sanket Dhuri, Consultant Homeopath April 14, 2021
A futuristic Vision of a Healthcare Entrepreneur: Shyatto Raha, CEO, and Founder of MyHealthcareApril 12, 2021
Saher Mehdi, Founder and Chief Scientist at wellOwise talks about aspects making healthcare more equitable and reachableApril 10, 2021
Wide variety of therapies to address autism in children explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 09, 2021
Allopathic and Homeopathic medicines should not be taken together says Dr. Sunil Mehra, Homeopath ConsultantApril 08, 2021
The charm of homeopathic medicine is that it can be taken with conventional medicines – Dr. Shruthi Shridhar, Consulting Homeopath April 08, 2021
Dissociative Identity Disorder and associated concepts explained by Dr. Vinod Kumar, Psychiatrist and Head of Mpower - The Centre (Bangalore) April 07, 2021
Dissociative Identity Disorder explained by Dr. Shilpa Jasubhai, Clinical PsychologistApril 05, 2021
Sehat Ki Baat, Karishma Ke Saath- Episode 6 Healthy Diet For Boosting Metabolism Which Can Help Thyroid Patients April 03, 2021
Significant Pointers on Kidney Health by Dr. Santosh Waigankar, Consultant Urooncologist and Robotic Surgeon at Kokilaben Dhirubhai Ambani HospitalApril 01, 2021
Dr. Vaishal Kenia, Ophthalmologist Talks About the Different Possibilities Available for the Treatment of Glaucoma Depending Upon Their Type and SeverityMarch 30, 2021
No Definitive Role of Diet in Treatment of Lymphedema but Intake of Calories, Salt and Long Chain Fatty Acids should be controlled says Dr. Ramani CVMarch 30, 2021
Dr. Kiran Chandra Patro, Senior Nephrologist Talks About Dialysis as the Temporary Process and Not a Permanent Cure for the Patients of Renal DysfunctionMarch 30, 2021
Two out of three new chronic kidney disease patients are found to have diabetes or hypertension informs Dr. Sreeharsha HarinathaMarch 30, 2021
Glaucoma Treatment: Medications or Surgery? A valuable piece of advice from Dr. Pranay Kapdia, Chairman and Medical Director of Kapadia Eye CareMarch 25, 2021
Dr. Shraddha Satav, Consultant Ophthalmologist Recommends that Everybody After 40, Should Go for the Complete Eye Checkup at Regular IntervalMarch 25, 2021